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A BS TR AC T
BACKGROUND
Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in 
phase 2 studies in patients with hepatitis B e antigen (HBeAg)–negative chronic hepa-
titis B.
METHODS
In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-
negative chronic hepatitis B who had not previously been treated with a nucleoside 
analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily for a 
minimum of 52 weeks. The primary efficacy end point was histologic improvement 
(a decrease by at least two points in the Knodell necroinflammatory score, without 
worsening of fibrosis).
RESULTS
Histologic improvement after 48 weeks of treatment occurred in 208 of 296 patients 
in the entecavir group who had adequate baseline liver-biopsy specimens that could 
be evaluated (70 percent), as compared with 174 of 287 such patients in the lami-
vudine group (61 percent, P = 0.01). More patients in the entecavir group than in the 
lamivudine group had undetectable serum hepatitis B virus (HBV) DNA levels ac-
cording to a polymerase-chain-reaction assay (90 percent vs. 72 percent, P<0.001) 
and normalization of alanine aminotransferase levels (78 percent vs. 71 percent, 
P = 0.045). The mean reduction in serum HBV DNA levels from baseline to week 48 
was greater with entecavir than with lamivudine (5.0 vs. 4.5 log [on a base-10 scale] 
copies per milliliter, P<0.001). There was no evidence of resistance to entecavir. 
Safety and adverse-event profiles were similar in the two groups.
CONCLUSIONS
Among patients with HBeAg-negative chronic hepatitis B who had not previously 
been treated with a nucleoside analogue, the rates of histologic improvement, viro-
logic response, and normalization of alanine aminotransferase levels were signifi-
cantly higher at 48 weeks with entecavir than with lamivudine. The safety profile 
of the two agents was similar, and there was no evidence of viral resistance to 
entecavir. (ClinicalTrials.gov number, NCT00035789.)
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Hepatitis B virus (HBV) infection is a serious global health concern. Approxi-mately 350 million people worldwide are 
chronically infected, and 500,000 to 1.2 million 
deaths per year are attributed to HBV-associated 
complications.1,2 A common variant of HBV in-
fection occurs in patients who test negative for 
hepatitis B e antigen (HBeAg) and positive for an-
tibodies against HBeAg (anti-HBe) and in whom 
serum HBV DNA and alanine aminotransferase 
levels remain persistently or intermittently elevat-
ed.3-5 The median worldwide prevalence of HBeAg-
negative disease in hepatitis B surface antigen 
(HBsAg)–positive carriers was reported to be 33 
percent in 2002 and is increasing.5
HBeAg-negative HBV develops spontaneously 
through mutations in the precore or core promoter 
regions of the viral genome such that HBeAg is 
no longer expressed or is down-regulated, and it 
has been suggested that this gives the mutant an 
immunologic advantage over wild-type HBV.3,4 
However, HBeAg-negative chronic hepatitis B is 
a heterogeneous condition, and wild-type HBV 
may also be responsible for disease activity in 
some patients.6,7 The clinical profile of HBeAg-
negative chronic hepatitis B differs from that of 
HBeAg-positive disease in that patients are typi-
cally older,4 serum HBV DNA levels are usually 
lower,8,9 and liver disease tends to fluctuate.10-12 
Patients with HBeAg-negative chronic hepatitis B 
have more advanced liver disease, and the likeli-
hood of spontaneous remission is very low.4,11
The end point of treatment for HBeAg-negative 
chronic hepatitis B is unknown. HBeAg loss or 
seroconversion cannot be used to assess response, 
and treatment usually focuses on suppression of 
HBV DNA and normalization of alanine amino-
transferase levels.13 Effective suppression of HBV 
DNA without development of resistance among 
HBeAg-negative patients has been associated with 
improved histologic findings in the liver and long-
term clinical benefit.14-16 Treatment guidelines 
support the use of interferon, lamivudine, or ad-
efovir for HBeAg-negative chronic hepatitis B in 
patients with viremia and elevated alanine ami-
notransferase levels.17-20 
Entecavir (Baraclude, Bristol-Myers Squibb) is 
a potent and highly selective inhibitor of HBV 
DNA polymerase.21 In a double-blind, randomized 
phase 3 study of HBeAg-positive patients who 
had not previously received a nucleoside analogue, 
entecavir resulted in significantly higher rates of 
histologic, virologic, and biochemical improve-
ment than did lamivudine, with a similar safety 
profile.22 The current study was designed to 
compare the efficacy and safety of entecavir with 
that of lamivudine (Epivir-HBV, GlaxoSmithKline) 
after 48 weeks of treatment in patients with 
HBeAg-negative chronic hepatitis B who had 
not previously received a nucleoside analogue.
Me thods
Study Design
The design of this randomized, double-blind, con-
trolled study was nearly identical to that of the 
study of HBeAg-positive patients reported by Chang 
et al. elsewhere in this issue of the Journal.22 Pa-
tients were recruited from 146 centers worldwide, 
including Europe and the Middle East (68 centers), 
Asia (25), Australia (11), North America (30), and 
South America (12), and received 0.5 mg of ente-
cavir or 100 mg of lamivudine once a day for a 
minimum of 52 weeks. Clinical management de-
cisions were made at week 52, on the basis of the 
results of branched-chain DNA assays (Quanti-
plex, Chiron) and alanine aminotransferase assays 
on serum samples obtained at week 48. 
Patients who had a response (defined by an 
HBV DNA level below 0.7 megaequivalents [MEq] 
per milliliter according to branched-chain DNA 
assay and an alanine aminotransferase level be-
low 1.25 times the upper limit of the normal 
range) or a nonresponse (defined by an HBV DNA 
level of 0.7 MEq per milliliter or greater) were to 
discontinue study treatment. 
Patients who had a response at week 48 and 
discontinued treatment were followed for 24 weeks 
after the cessation of treatment. In this way, we 
investigated whether the virologic and biochem-
ical benefits of antiviral therapy were sustained 
after the discontinuation of treatment. Patients 
who had only a virologic response (defined by an 
HBV DNA level below 0.7 MEq per milliliter and 
an alanine aminotransferase level of at least 1.25 
times the upper limit of normal) were offered con-
tinued therapy for up to 96 weeks.
The study was conducted in accordance with 
the ethics principles of the Declaration of Helsinki 
and was consistent with Good Clinical Practice 
guidelines and applicable local regulatory require-
ments. Written informed consent was obtained 
from all randomly assigned patients.
The study was designed by the sponsor (Bristol-
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Myers Squibb) in collaboration with expert hepa-
tologists who comprised the Benefits of Enteca-
vir for Hepatitis B Liver Disease (BEHoLD) Study 
Group. The sponsor collected the data, monitored 
the conduct of the study, performed the statisti-
cal analyses, and coordinated the writing of the 
manuscript with all authors. Data were unblind-
ed for statistical analysis after the database was 
locked. The authors had access to the complete 
study reports, were actively involved in data analy-
sis and interpretation, and approved the final 
manuscript. The academic authors vouch for the 
veracity and completeness of the data and the data 
analyses.
 Study Population
Eligible patients were 16 years of age or older and 
had HBeAg-negative chronic hepatitis B and com-
pensated liver function (a total serum bilirubin 
level of 2.5 mg per deciliter [42.8 μmol per liter] 
or less, a prothrombin time not more than three 
seconds longer than normal or an international 
normalized ratio not greater than 1.5, a serum 
albumin level of at least 3.0 g per deciliter, and 
no history of variceal bleeding or hepatic enceph-
alopathy). Eligible patients also had detectable 
HBsAg for at least 24 weeks before screening, 
evidence of chronic hepatitis on a baseline liver-
biopsy specimen obtained within 52 weeks be-
fore randomization, evidence of HBV DNA by any 
commercial assay at least 2 weeks before screen-
ing, undetectable HBeAg, detectable anti-HBe, a 
serum HBV DNA level of at least 0.7 MEq per mil-
liliter according to the branched-chain DNA assay 
at screening, and a serum alanine aminotrans-
ferase level 1.3 to 10.0 times the upper limit of 
normal at screening. 
Exclusion criteria included coinfection with 
hepatitis C, hepatitis D, or the human immuno-
deficiency virus; the presence of other forms of 
liver disease; use of interferon alfa, thymosin α, 
or antiviral agents with activity against hepatitis 
B within 24 weeks before randomization; previ-
ous lamivudine therapy lasting more than 12 
weeks; an alpha fetoprotein level greater than 
100 ng per milliliter; a history of ascites requir-
ing diuretics or paracentesis; and previous treat-
ment with entecavir.
Efficacy End Points
The primary and secondary efficacy end points 
were the same as those in the study of HBeAg-
positive patients,22 except that HBeAg loss and 
seroconversion were not secondary end points in 
the present study. The primary efficacy end point 
was the proportion of patients with histologic 
improvement, defined as improvement by at least 
two points in the Knodell necroinflammatory 
score, with no worsening in the Knodell fibrosis 
score at week 48, relative to baseline.23 
Secondary efficacy end points at week 48 in-
cluded the reduction in the HBV DNA level from 
baseline and the proportion of patients with un-
detectable HBV DNA, as measured by the Roche 
COBAS Amplicor polymerase-chain-reaction (PCR) 
assay (version 2.0; lower limit of quantification, 
300 copies per milliliter); the decrease in the Ishak 
fibrosis score; and normalization of serum alanine 
aminotransferase (less than 1.0 times the upper 
limit of normal).
Safety Analysis
The safety analysis included data from all 638 
treated patients during treatment, including the 
second year of treatment for patients who contin-
ued for more than 52 weeks. The primary safety 
end point was the proportion of patients who dis-
continued the study medication because of clinical 
or laboratory-determined adverse events. Other 
safety evaluations included analyses of adverse 
events, serious adverse events, and deaths. Flares 
of hepatitis during treatment were defined as el-
evations in the alanine aminotransferase level to 
more than twice the baseline level and to more 
than 10 times the upper limit of normal. Post-
treatment flares were defined as elevations in 
alanine aminotransferase to more than twice the 
reference level and to more than 10 times the up-
per limit of normal, where the reference level was 
the lesser of the baseline value and the end-of-
treatment value.
Resistance Analysis
Two sampling schemes were used to identify 
emerging HBV polymerase substitutions that may 
be associated with reduced susceptibility to ente-
cavir. Paired samples from 211 randomly selected 
patients in the entecavir group were genotypically 
analyzed. HBV DNA was extracted and amplified 
with the use of PCR, and amino acids 1 through 
344 of the reverse transcriptase were sequenced as 
described elsewhere.24 Substitutions that emerged 
during therapy were inserted into recombinant 
clones and analyzed in cell-culture phenotypic 
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assays for susceptibility to entecavir.24 The second 
sampling scheme involved genotypic and pheno-
typic analyses of all paired samples from all pa-
tients meeting the criterion for virologic rebound 
(defined as a confirmed increase in the HBV DNA 
level by at least 1 log [on a base-10 scale] copy per 
milliliter from the nadir value, according to PCR 
assay, while the patient was receiving the study 
medication).
Statistical Analysis
A two-stage evaluation was planned. First, non-
inferiority to lamivudine was tested, and if non-
inferiority was established, a second test for su-
periority was conducted. The planned sample size, 
315 per group, had 90 percent power to demon-
strate noninferiority with respect to the primary 
efficacy end point, assuming response rates of 60 
percent for lamivudine and 64 percent for enteca-
vir, a 25 percent rate of missing biopsy specimens 
obtained at week 48, and a −10 percent boundary 
for the 95 percent lower confidence limit for the 
difference in proportions. The study had a single 
primary end point (histologic improvement).
Patients with missing or inadequate biopsy 
specimens obtained at week 48 were considered 
not to have had a histologic response. In propor-
tion analyses of HBV DNA levels and alanine 
aminotransferase levels, treated patients with a 
missing value for an end point were considered 
not to have had a response for that end point. To 
compare the means of continuous variables, we 
used t-tests based on linear regression models, 
adjusted for baseline measurements. There were 
no interim analyses of efficacy. All reported P val-
ues are two-sided and were not adjusted for mul-
tiple testing.
R esult s
Study Population
Of 1468 patients who were enrolled and screened, 
648 were randomly assigned to treatment (331 to 
the entecavir group and 317 to the lamivudine 
group), and 638 (325 in the entecavir group and 
313 in the lamivudine group) received, in a blinded 
fashion, at least one dose of study drug. Of these 
638 patients, 583 had adequate baseline liver-biopsy 
specimens with a Knodell necroinflammatory 
score of 2 or greater; 31 of 296 patients receiving 
entecavir (10 percent) and 37 of 287 patients re-
ceiving lamivudine (13 percent) who had baseline 
liver-biopsy specimens had missing specimens at 
week 48. The two treatment groups were well 
balanced at baseline (Table 1). Of the 820 pa-
tients not randomly assigned to treatment, 774 
did not meet one or more of the inclusion criteria.
Three hundred eleven patients assigned to 
receive entecavir (96 percent) and 296 patients 
assigned to receive lamivudine (95 percent) com-
pleted 52 weeks of treatment. No patient discon-
tinued treatment because of treatment failure or 
lack of efficacy during the 52-week, blinded treat-
ment period.
Histologic and Biochemical Response
After criteria for noninferiority were met, we con-
ducted tests for superiority. Histologic improve-
ment occurred in significantly more patients in 
the entecavir group than in the lamivudine group 
at week 48 (70 percent vs. 61 percent, P = 0.01) 
(Table 2). There was no histologic improvement 
in 26 percent of patients in the lamivudine group 
and 19 percent of patients in the entecavir group. 
Treatment with entecavir or lamivudine resulted 
in improved Ishak fibrosis scores in 36 percent and 
38 percent of the patients, respectively (P = 0.65). 
The alanine aminotransferase level was normal-
ized in significantly more patients treated with 
entecavir than those treated with lamivudine at 
week 48 (78 percent vs. 71 percent, P = 0.045) 
(Table 3).
Virologic and Serologic Response
The mean reduction from baseline in serum HBV 
DNA levels according to PCR assay at week 48 
was significantly greater in the entecavir group 
than in the lamivudine group (5.0 log copies vs. 
4.5 log copies per milliliter, P<0.001) (Table 3 and 
Fig. 1B). HBV DNA levels in the entecavir group 
fell continuously during treatment, and 90 percent 
of the patients had undetectable levels at week 48 
according to PCR assay. In contrast, HBV DNA 
levels in the lamivudine group remained distrib-
uted over a wide range of values, and 72 percent 
of the patients had undetectable levels at week 48 
according to PCR assay (P<0.001) (Table 3 and 
Fig. 1A). HBsAg loss had occurred in one patient 
in each treatment group at week 48.
Responses at Week 48 and after Treatment
At week 48, 275 patients in the entecavir group 
(85 percent) and 245 patients in the lamivudine 
group (78 percent) had a response (P = 0.04), as 
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defined by the protocol (HBV DNA level, <0.7 MEq 
per milliliter, according to branched-chain DNA 
assay; alanine aminotransferase level, <1.25 times 
the upper limit of normal). Thirty-four patients 
in the entecavir group (10 percent) and 34 in the 
lamivudine group (11 percent) had a virologic re-
sponse (HBV DNA level, <0.7 MEq per milliliter; 
alanine aminotransferase level, ≥1.25 times the 
upper limit of normal). Three patients in the en-
tecavir group (<1 percent) and 18 in the lamivu-
dine group (6 percent) had a nonresponse (HBV 
DNA level, ≥0.7 MEq per milliliter).
Table 1. Demographic and Baseline Characteristics of the Patients.*
Characteristic Entecavir (N = 325) Lamivudine (N = 313) P Value
Age — yr 44±11 44±11 1.00
Male sex — no. (%) 248 (76) 236 (75) 0.85
Race or ethnic group — no. (%)†
White 193 (59) 176 (56) 0.74
Asian 122 (38) 129 (41)
Black 8 (2) 7 (2)
Other 2 (<1) 1 (<1)
Region — no. (%)
Europe and the Middle East 156 (48) 148 (47) 1.00
Asia and Australia 106 (33) 104 (33)
South America 35 (11) 34 (11)
North America 28 (9) 27 (9)
Knodell necroinflammatory score‡ 8.0±2.7 7.7±2.8 0.18
Ishak fibrosis score‡ 2.4±1.2 2.5±1.3 0.31
≥3 (bridging fibrosis) — % 43 41 0.68
≥5 (cirrhosis) — % 5 10 0.06
Mean HBV DNA level
By branched-chain DNA assay — MEq/ml 1.2±1.0 1.2±1.0 1.00
By PCR assay — log copies/ml 7.6±1.8 7.6±1.7 1.00
HBeAg-negative — no. (%) 322 (99) 309 (99) 0.72
Anti-HBe-positive — no. (%) 323 (99) 312 (100) 1.00
Viral genotype — no. (%) 
A 33 (10) 33 (11) 0.45
B 46 (14) 60 (19)
C 57 (18) 51 (16)
D 157 (48) 135 (43)
Other, indeterminate, or missing 32 (10) 34 (11)
Alanine aminotransferase — IU/liter 141±114.7 143±119.4 0.83
Prior anti-HBV therapy — no. (%) 49 (15) 45 (14)
Interferon 42 (13) 39 (12) 0.91
Lamivudine 9 (3) 12 (4) 0.51
* Plus–minus values are means ±SD. Percentages may not sum to 100 because of rounding. The Knodell inflammatory 
score can range from 0 to 18, with higher scores indicating more severe chronic hepatitis. The Ishak fibrosis score is 
based on a scale of 0 to 6, where 0 indicates no fibrosis and 5 or higher indicates cirrhosis. HBV denotes hepatitis B vi-
rus, PCR polymerase chain reaction, and HBeAg hepatitis B e antigen.
† Race or ethnic group was determined by the investigator.
‡ Adequate baseline biopsy specimens were available for 303 patients in the entecavir group and 293 patients in the la-
mivudine group.
Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF HONG KONG on August 1, 2007 . 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 354;10 www.nejm.org march 9, 20061016
Among the patients who had a protocol-
defined response at week 48 and who discontin-
ued study treatment, 124 of 259 patients in the 
entecavir group (48 percent) and 78 of 220 pa-
tients in the lamivudine group (35 percent) had a 
sustained response for at least 24 weeks after the 
discontinuation of treatment.
Resistance
There was no evidence of resistance to entecavir 
at week 48 in paired samples from 211 randomly 
selected patients in the entecavir group. Further-
more, 5 patients receiving entecavir (2 percent) and 
25 patients receiving lamivudine (8 percent) had 
virologic rebound. Genotypic analysis at week 48 
of isolates from the five patients treated with en-
tecavir revealed no emerging substitutions when 
comparing baseline and samples obtained at week 
48, and samples obtained at week 48 retained 
full phenotypic susceptibility to entecavir. Geno-
typic analysis of  isolates obtained at week 48 from 
the 25 patients in the lamivudine group who had 
virologic rebound revealed that 20 (80 percent) 
had mutations in the YMDD (tyrosine, methio-
nine, aspartate, aspartate) motif of the HBV poly-
merase gene.
Safety and Adverse Events
The mean exposure to study therapy was 56 weeks 
for the entecavir group and 56 weeks for the la-
Table 2. Histologic Improvement at Week 48 (Primary Study End Point).
End Point
Entecavir 
(N = 325)
Lamivudine 
(N = 313)
Difference Estimate 
(95% CI)* P Value
Adequate baseline biopsy specimen and Knodell 
necroinflammatory score ≥2 — no.
296 287
Improvement — no. (%)† 208 (70) 174 (61) 9.6 (2.0–17.3) 0.01
No improvement — no. (%) 57 (19) 76 (26)
Mean Knodell necroinflammatory score‡
Baseline  8.1 7.8
Week 48 4.2 4.6
* The difference estimate was calculated for the entecavir group as compared with the lamivudine group. CI denotes con-
fidence interval.
† Histologic improvement was defined as a decrease by at least 2 points in the Knodell necroinflammatory score, with no 
worsening in the fibrosis component of the score.
‡ There were 265 treated patients in the entecavir group and 250 in the lamivudine group with evaluable pairs of biopsy 
specimens.
Table 3. Virologic and Biochemical End Points at Week 48.*
End Point
Entecavir
(N = 325)
Lamivudine
(N = 313)
Difference Estimate 
(95% CI)† P Value
Virologic
HBV DNA <300 copies/ml by PCR assay — 
no. (%) 
293 (90) 225 (72) 18.3 (12.3 to 24.2) <0.001
HBV DNA <0.7 MEq/ml by branched-chain 
DNA assay — no. (%)
309 (95) 279 (89)  5.9 (1.8 to 10.1) 0.005
Mean change in HBV DNA level from base-
line by PCR assay — log copies/ml‡
−5.0±1.7 −4.5±1.9 −0.43 (−0.6 to −0.3) <0.001
Biochemical
ALT normalization (≤1.0× ULN) — no. (%) 253 (78) 222 (71) 6.9 (0.2 to 13.7) 0.045
* Plus–minus values are means ±SD. CI denotes confidence interval, ALT alanine aminotransferase, and ULN the upper 
limit of the normal range.
† The difference estimate was calculated for the entecavir group as compared with the lamivudine group.
‡ There were 314 patients in the entecavir group and 295 patients in the lamivudine group with paired baseline and HBV 
DNA measurements obtained at week 48. Samples with undetectable HBV DNA levels were assigned a value of 299 
copies per milliliter.
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mivudine group. The frequency of adverse events 
during treatment was similar between the two 
treatment groups (Table 4). The most frequent ad-
verse events were headache, upper respiratory tract 
infection, upper abdominal pain, influenza, naso-
pharyngitis, dyspepsia, fatigue, back pain, arthral-
gia, diarrhea, insomnia, cough, nausea, and my-
algia, most of which were of mild-to-moderate 
severity. The frequencies of serious adverse events 
were also similar in the two treatment groups. 
There were fewer discontinuations due to adverse 
events in the entecavir group (six) than in the la-
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Figure 1. Distribution of Patients According to HBV DNA Levels (Panel A) and Mean HBV DNA Levels through 
Week 48 (Panel B).
Panel A shows HBV DNA levels in entecavir-treated patients and lamivudine-treated patients. The numbers above 
the columns of circles are the numbers of patients. The diameters of the circles are proportional to the percentages 
of patients with the specified DNA levels; the percentages represented by the circles in each column total 100. The 
log (on a base-10 scale) HBV DNA levels indicated on the y axis reflect the range of levels with that exponent; an 
HBV DNA level of less than 300 copies per milliliter was below the level of detection with the use of polymerase-
chain-reaction (PCR) analysis. Panel B shows mean HBV DNA levels according to PCR through week 48 among the 
treated patients. The horizontal dashed line represents the lower limit of detection of the PCR assay.
This figure has been corrected from the version published on March 9, 2006.
Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF HONG KONG on August 1, 2007 . 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 354;10 www.nejm.org march 9, 20061018
mivudine group (nine), and no patient discontin-
ued study therapy because of an alanine amino-
transferase flare.
Elevations in alanine aminotransferase levels 
rarely occurred during treatment and were ob-
served with similar frequencies in the two treat-
ment groups (Table 4). Alanine aminotransferase 
flares during treatment were observed in three 
patients in the entecavir group and five patients 
in the lamivudine group. In the entecavir group, 
two of the alanine aminotransferase flares oc-
curred early in therapy and were associated with 
a reduction in HBV DNA by at least 2 log copies 
per milliliter, according to branched-chain DNA 
assay. The other flare occurred one day after the 
last dose of entecavir and resolved spontaneously 
within two months. None of the entecavir-treated 
patients had hepatic decompensation.
In the lamivudine group, two of the five ala-
nine aminotransferase flares were associated with 
a reduction in HBV DNA by at least 2 log copies 
per milliliter. The other three flares were associ-
ated with increasing HBV DNA levels, and one 
was associated with the development of ascites.
Of the 297 patients in the entecavir group and 
263 patients in the lamivudine group who entered 
post-treatment follow-up by the data cut-off, ala-
nine aminotransferase level flares occurred in 23 
(8 percent) and 29 (11 percent), respectively, dur-
ing follow-up.
Two deaths, considered unrelated to study 
therapy, occurred during the treatment period, 
both in the entecavir group (Table 4). One patient, 
who had a history of cirrhosis, died at week 45, 
after hepatocellular carcinoma was diagnosed at 
week 42 of entecavir therapy. Pneumonia devel-
oped in the other patient, who had a history of 
diabetes mellitus and cirrhosis and subsequently 
died at week 8 from multiorgan failure.
Discussion
Suppression of viral replication is a principal goal 
of therapy in patients with HBeAg-negative chron-
ic hepatitis B. A retrospective analysis of long-term 
lamivudine therapy in HBeAg-negative patients 
showed that those with well-compensated cirrho-
sis who maintained HBV DNA suppression had 
reduced rates of hepatocellular carcinoma and pro-
gression of liver disease.16 These results are sup-
ported by Liaw et al., who showed that for pa-
tients with HBeAg-negative or HBeAg-positive 
chronic hepatitis B who had cirrhosis or advanced 
fibrosis, treatment with lamivudine slows the pro-
gression of liver disease, presumably by suppress-
ing viral replication and decreasing the resultant 
necroinflammatory response.25
In this trial, entecavir was associated with sig-
nificantly greater suppression of viral replication 
than was lamivudine, as measured by both the 
Table 4. Comparison of Safety Data.*
Timing and Event Entecavir (N = 325) Lamivudine (N = 313) P Value
no. of patients (%)
During treatment
Any adverse event 246 (76) 248 (79) 0.30
Serious adverse event 21 (6) 24 (8) 0.64
Discontinuation due to adverse event 6 (2) 9 (3) 0.44
ALT >2× baseline and >10× ULN† 3 (<1) 5 (2) 0.50
ALT >2× baseline and >5× ULN‡ 6 (2) 10 (3) 0.32
Death 2 (<1) 0 0.50
Post-treatment follow-up§
ALT >2× reference value and >10× ULN¶ 23 (8) 29 (11) 0.19
ALT >2× reference value and >5× ULN‡ 36 (12) 77 (29) <0.001
* ALT denotes alanine aminotransferase, and ULN upper limit of normal.
† According to the protocol, these findings constituted alanine aminotransferase flares during treatment.
‡ The analysis was conducted post hoc.
§ There were 297 patients in the entecavir group and 263 in the lamivudine group who had entered post-treatment as of 
the data cut-off.
¶ According to the protocol, these findings constituted post-treatment alanine aminotransferase flares. The reference lev-
el was the lesser of the baseline value and the end-of-treatment alanine aminotransferase values.
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proportion of patients who had undetectable lev-
els of HBV DNA 48 weeks after the start of treat-
ment and the magnitude of reduction in the level 
of HBV DNA from baseline. Significantly more 
patients had normalization of alanine amino-
transferase levels and histologic improvement af-
ter treatment with entecavir than after treatment 
with lamivudine. Although this suggests that en-
tecavir may be more effective than lamivudine in 
preventing adverse clinical outcomes among pa-
tients with HBeAg-negative chronic hepatitis B, 
longer surveillance is necessary.
The potent suppression of viral replication as-
sociated with treatment with entecavir decreases 
the risk of development of resistant virus. In this 
study, there was no evidence of the emergence of 
resistance in any entecavir-treated patients. Al-
though several emerging resistance substitutions 
occurred, none were present in more than three 
patients and, most important, none resulted in 
reduced susceptibility to entecavir when tested in 
phenotypic assays. Monitoring of entecavir treat-
ment to determine long-term resistance rates is 
ongoing.
Lamivudine has been used extensively for pa-
tients with HBeAg-negative chronic hepatitis B, 
with few adverse effects. The similar safety pro-
files of entecavir and lamivudine in this study 
demonstrate that entecavir has few adverse reac-
tions; surveillance of the safety of long-term en-
tecavir treatment continues.
Optimal treatments for patients with HBeAg-
negative chronic hepatitis B continue to evolve. 
For most patients, long-term treatment is neces-
sary to maintain viral suppression and remission 
of liver disease. Pegylated interferon alfa demon-
strated efficacy but has an adverse-event profile 
similar to that of interferon alfa.26-29 One year of 
treatment with lamivudine produced histologic 
improvement in 60 percent of patients, with re-
sistance rates of up to 27 percent.30,31 Treatment 
with adefovir for one year resulted in histologic 
improvement in 64 percent and normalization of 
the alanine aminotransferase level in 72 percent 
of patients, with no evidence of resistance.32 After 
four years of treatment with adefovir, resistance 
developed in up to 18 percent of patients.33
The present study of entecavir and lamivudine 
in patients with HBeAg-negative chronic hepati-
tis B complements a similar trial in patients with 
HBeAg-positive chronic hepatitis B.22 Entecavir 
offers the potential to control HBV replication, 
improve histology, and arrest or reverse the pro-
gression of liver disease consistently and predict-
ably. Together with its safety profile, this suggests 
that entecavir should be considered as a primary 
therapy for HBeAg-negative chronic hepatitis B 
in patients not previously treated with a nucleo-
side analogue.
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CORRECTION
Entecavir versus Lamivudine for Patients with
HBeAg-Negative Chronic Hepatitis B
Entecavir versus Lamivudine for Patients with HBeAg-Negative
Chronic Hepatitis B . On page 1017, the data plots in Figure 1B are
incorrectly placed. A revised figure is shown here. The figure has also
been corrected on the Journal ’s Web site at www.nejm.org. We regret
the error.
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